Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 901–1,000 of 1,006
Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype
Pacheco-Velázquez, S. C., Robledo‐Cadena, D. X., Hernández‐Reséndiz, I., Gallardo‐Pérez, J. C., Moreno‐Sánchez, R., & Rodríguez‐Enríquez, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00015 · Cited by 64
Mayer, A., & Vaupel, P. W. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-7411-1_28 · Cited by 75
Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function
DONAHUE, R. J., RAZMARA, M., HOEK, J. B., & KNUDSEN, T. B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0262com · Cited by 64
“The p53 tumor suppressor is a homotetrameric transcription factor induced by DNA damage (1, 2), hypoxia (3, 4 ), and ribonucleotide perturbation (5, 6). These stress imbalances can trigger p53-dependent cell cycle arrest or programmed cell death (apoptosis) in a variety of cell types (7‐9).”
Backgroundp53 in the CNS: Perspectives on Development, Stem Cells, and Cancer
Mendrysa, S. M., Ghassemifar, S., & Malek, R. A. (2011) · Genes & Cancer · doi:10.1177/1947601911409736 · Cited by 74
p53 Homologue p63 Represses Epidermal Growth Factor Receptor Expression
Nishi, H., Senoo, M., Nishi, K., Murphy, B., Rikiyama, T., Matsumura, Y., Habu, S., & Johnson, A. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101241200 · Cited by 70
A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance
Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700913.x · Cited by 71
Bcl-x expression influences keratinocyte cell survival but not terminal differentiation.
Pena, J. C., Fuchs, E. V., & Thompson, C. B. (1997) · PubMed · Cited by 73
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0494-6 · Cited by 64
“In addition, hypoxia is known to select cells that have lost their apoptotic potential [66], so it is also likely that an initial apoptotic response to AURKA inhibition might have occurred, leading to expansion of apoptotic resistant cells and failure to detect apoptotic cells at the endpoint.”
BackgroundThe impact of anaemia on outcome in cancer
Clarke, H., & Pallister, C. J. (2005) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2004.00664.x · Cited by 68
Ding, G., Huang, G., Liu, H., Liang, H., Ni, Y., Ding, Z., Ni, G.-Y., & Hua, H.-W. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1795-3 · Cited by 65
“This condition triggers tumor cells to undergo genetic and adaptive alterations that permit them to continue to survive and proliferate in such conditions [14, 15].”
BackgroundTumour Hypoxia: Impact on Biology, Prognosis and Treatment of Solid Malignant Tumours
Weinmann, M., Belka, C., & Plaßwilm, L. (2004) · Oncology Research and Treatment · doi:10.1159/000075611 · Cited by 73
Ord, J., Agrawal, S., Thamboo, T. P., Roberts, I. S. D., Campo, L., Turley, H., Han, C., Fawcett, D. W., Kulkarni, R., Cranston, D., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.112 · Cited by 64
Liu, X., Kirschenbaum, A. M., Kang, Y., Shen, Y., & Levine, A. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406577200 · Cited by 68
Targeting the tumor vascular compartment to improve conventional cancer therapy
Féron, O. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.08.008 · Cited by 72
Antitumour and pro-apoptotic actions of highly unsaturated fatty acids in glioma
LEAVER, H. A., Bell, H. S., Rizzo, M. T., Ironside, J. W., Gregor, A., Wharton, S. B., & Whittle, I. R. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0336 · Cited by 64
Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis
Liu, T., Laurell, C., Selivanova, G., Lundeberg, J., Nilsson, P., & Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402022 · Cited by 64
“Hypoxia or anoxia has been shown to induce p53 accumulation and apoptosis.(6,7) However, p53 activation by hypoxia does not appear to induce expression of classical p53 target genes such as p21, MDM2 and Bax, but can still mediate transrepression of certain genes such as a-tubulin.”
BackgroundPost, D. E., Devi, N. S., Li, Z., Brat, D. J., Kaur, B., Nicholson, A. C., Olson, J. J., Zhang, Z., & Meir, E. G. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1432 · Cited by 72
“01% Pronase for 20 minutes at 4°C, (2) primary antibody for adenovirus hexon is Mb805 (Chemicon) diluted 1:1000 for 1 hour at 35°C, and (3) secondary antibody treatment for 15 minutes at 35°C.”
Methodde Heredia, M. L., Izquierdo, J. M., & Cuezva, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7430 · Cited by 69
Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.
Treat, J., Johnson, E., Langer, C. J., Belani, C. P., Haynes, B., Greenberg, R., Rodriquez, R., Drobins, P., Miller, W. T., Meehan, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3524 · Cited by 64
Zschaeck, S., Haase, R., Abolmaali, N., Perrin, R. L., Stützer, K., Appold, S., Steinbach, J., Kotzerke, J., Zips, D., Richter, C., et al. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1074720 · Cited by 67
Stojkov, D., Gigon, L., Peng, S., Łukowski, R., Ruth, P., Karaulov, A. V., Rizvanov, A. A., Barlev, N. A., Yousefi, S., & Simon, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826515 · Cited by 69
“It has been described that hypoxia inhibits apoptosis by inducing a number of glycolytic enzymes, including GAPDH, allowing for the ongoing production of ATP, which is critical for neutrophil survival and function (73).”
BackgroundCellular and Molecular Mechanisms Underlying Oxygen-Dependent Radiosensitivity
Liu, C., Lin, Q., & Yun, Z. (2015) · Radiation Research · doi:10.1667/rr13959.1 · Cited by 68
“Furthermore, the p53-deficient cells also resisted hypoxiainduced apoptosis in xenografts (45).”
BackgroundNeoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?
Glynne‐Jones, R., & Hoskin, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3133 · Cited by 63
Iakovlev, V. V., Pintilie, M., Morrison, A. J., Fyles, A., Hill, R. P., & Hedley, D. W. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700680 · Cited by 63
Molecular Basis for the Inhibition of Hypoxia-Induced Apoptosis by 2-Deoxy-d-ribose
Ikeda, R., Furukawa, T., Kitazono, M., Ishitsuka, K., Okumura, H., Tani, A., Sumizawa, T., Haraguchi, M., Komatsu, M., Uchimiya, H., et al. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6432 · Cited by 66
HIF-1α and p53: the ODD couple?
Fels, D. R., & Koumenis, C. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.06.009 · Cited by 63
Tercel, M., Lee, A. E., Hogg, A., Anderson, R. F., Lee, H. H., Siim, B. G., Denny, W. A., & Wilson, W. R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010202l · Cited by 63
Tajima, N., Schönherr, K., Niedling, S., Kaatz, M., Kanno, H., Schönherr, R., & Heinemann, S. H. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.096818 · Cited by 61
“2003); (2) selection for tumour cells with diminished sensitivity to radiotherapy or chemotherapy (Graeber et al. 1996; Shannon et al. 2003); and (3) the promotion of migration and metastatic spread (Brizel et al.”
BackgroundWeinmann, M., Jendrossek, V., Güner, D., Goecke, B., & Belka, C. (2004) · The FASEB Journal · doi:10.1096/fj.04-1918fje · Cited by 68
“Several groups have already provided strong evidence that hypoxia-induced apoptosis and cell death are mainly triggered by Bcl-2 inhibitable mitochondrial death pathways (10, 15, 38, 39).”
BackgroundPapadopoulos, M. C., Koumenis, I. L., Xu, L., & Giffard, R. G. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00134.x · Cited by 63
Tachibana, O., Lampe, J. B., Kleihues, P., & Ohgaki, H. (1996) · Acta Neuropathologica · doi:10.1007/s004010050542 · Cited by 63
Weinmann, M., Jendrossek, V., Handrick, R., Güner, D., Goecke, B., & Belka, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207481 · Cited by 67
“It has been shown that in vitro modelling of this in vivo situation by repeated exposure to conditions of severe hypoxia induces apoptosis and selects for cells with defects in relevant apoptotic pathways (Graeber et al., 1996; Kim et al., 1997).”
BackgroundComputational pathology: Exploring the spatial dimension of tumor ecology
Nawaz, S., & Yuan, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.11.018 · Cited by 59
Matschke, J., Riffkin, H., Klein, D., Handrick, R., Lüdemann, L., Metzen, E., Shlomi, T., Stuschke, M., & Jendrossek, V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6589 · Cited by 68
“…are only partially understood, loss of the tumor suppressor p53 and deregulated expression of DNA repair enzymes, anti-apoptotic proteins of the Bcl-2 family, and free radical scavenging systems have been implicated in the tolerance of tumor cells to cycling hypoxia (21, 26, 36, 42, 74, 80).”
A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas.
Pena, J. C., Rudin, C. M., & Thompson, C. B. (1998) · PubMed · Cited by 71
Targeting tumor blood vessels: an adjuvant strategy for radiation therapy
Siemann, D. W., Warrington, K. H., & Horsman, M. R. (2000) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(00)00243-7 · Cited by 62
Zhou, J., Callapina, M., Goodall, G. J., & Brüne, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1437 · Cited by 62
Gilead, A., Meir, G., & Neeman, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11583 · Cited by 63
Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
Hardee, M. E., Kirkpatrick, J. P., Shan, S., Snyder, S. A., Vujaskovic, Z., Rabbani, Z. N., Dewhirst, M. W., & Blackwell, K. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602846 · Cited by 62
“…UK Keywords: erythropoietin; angiogenesis; tumour growth Low oxygen tension (pO2) promotes the selection of cells with reduced apoptotic potential (Graeber et al, 1996), increases the frequency of mutation (Reynolds et al, 1996), induces genes promoting angiogenesis (Dachs and Chaplin, 1998) and…”
BackgroundMeasuring Hypoxia in Solid Tumours&Is There a Gold Standard?
Olive, P. L. (2001) · Acta Oncologica · doi:10.1080/02841860152708189 · Cited by 63
Le, Q., Moon, J., Redman, M. W., Williamson, S. K., Lara, P. N., Goldberg, Z., Gaspar, L. E., Crowley, J. J., Moore, D. F., & Gandara, D. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3868 · Cited by 63
David-Pfeuty, T., Nouvian-Dooghe, Y., Sirri, V., Roussel, P., & Hernandez-Verdun, D. (2001) · Oncogene · doi:10.1038/sj.onc.1204741 · Cited by 74
“…been recognized only recently that wt p53 could also be activated and initiate these pathways in response to other types of signals, like hypoxia (Graeber et al., 1996), oncogenes (via the Arf protein; for review see Sharpless and DePinho, 1999) and depletion of ribonucleotide triphosphates…”
BackgroundOrigins and selection of p53 mutations in lung carcinogenesis
Rodin, S. N., & Rodin, A. S. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.08.005 · Cited by 70
Dunst, J., Pigorsch, S. U., Hänsgen, G., Hintner, I., Lautenschläger, C., & Becker, A. (1999) · Strahlentherapie und Onkologie · doi:10.1007/bf02742340 · Cited by 62
A survey of reactive oxygen species and their role in dermatology
Maccarrone, M., Catani, M. V., Iraci, S., Melino, G., & Finazzi‐Agrò, A. (1997) · Journal of the European Academy of Dermatology and Venereology · doi:10.1016/s0926-9959(97)00076-7 · Cited by 66
Hypoxia-inducible factors as key regulators of tumor inflammation
Mamlouk, S., & Wielockx, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.27901 · Cited by 61
“Cellular hypoxia has been shown to induce mutations(8) and increase selection for malignant and metastatic cells.(9,10) More critically, the presence of hypoxia in solid tumors hampers radiotherapy, where sensitivity to irradiation (DNA damage) requires oxidation in aerobic conditions.”
BackgroundLee, W., Huang, S.-C., Hsu, K., Tzeng, C., & Shen, W.-L. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.034 · Cited by 61
“reduce acid-mediated cell death [41].”
Greijer, A. E., de Jong, M. C., Scheffer, G. L., Shvarts, A., van Diest, P. J., & van der Wall, E. (2005) · Analytical Cellular Pathology · doi:10.1155/2005/236045 · Cited by 62
“hypoxia may induce resistance by selecting for cells with diminished capability of apoptosis [10].”
BackgroundBentzen, L., Keiding, S., Horsman, M. R., Grönroos, T. J., Hansen, S. B., & Overgaard, J. (2002) · Acta Oncologica · doi:10.1080/02841860260088863 · Cited by 61
Free radicals and reactive oxygen species in programmed cell death
Anderson, K. M., Seed, T. M., Ou, D., & Harris, J. E. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0521 · Cited by 66
Yano, M., Shiozaki, H., Inoue, M., Tamura, S., Doki, Y., Yasuda, T., Fujiwara, Y., Tsujinaka, T., & Monden, M. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6362-0 · Cited by 61
Hedenus, M., Vansteenkiste, J., Kotasek, D., Austin, M., & Amado, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.434 · Cited by 61
Apoptosis in tumorigenesis and cancer therapy
Fisher, D. E. (1997) · Frontiers in bioscience · doi:10.2741/a197 · Cited by 70
“as necrosis) in transformed cells in vitro (234, 235), and correlates well spatially with areas of apoptosis in vivo (236).”
Azuma, C., Raleigh, J. A., & Thrall, D. Ε. (1997) · Radiation Research · doi:10.2307/3579536 · Cited by 62
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer
McEvoy, L., O’Toole, S. A., Spillane, C. D., Martin, C. M., Gallagher, M. F., Stordal, B., Blackshields, G., Sheils, O. M., & O’Leary, J. J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1539-8 · Cited by 64
“Hypoxia has been shown to induce platinum resistance through interference with a number of biological molecules such as L1-cell adhesion molecule (L1-CAM) [16], signal transducer and activator of transcription 3 (STAT3) [15] and p53 [17].”
BackgroundLadelfa, M. F., Toledo, M. F., Laiseca, J. E., & Monte, M. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3652 · Cited by 61
“In fact, hypoxia promotes the selection of tumor cells harboring mutant p53 (49).”
BackgroundHypoxia and VEGF mRNA Expression in Human Tumors
Ziemer, L. S., Koch, C. J., Maity, A. M., Magarelli, D. P., Horan, A. D., & Evans, S. M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900195 · Cited by 60
“The first is that hypoxia causes genetic instability [6], which allows selection for a more aggressive tumor phenotype [ 7 ].”
BackgroundSelf-citationTrédan, O., Garbens, A., Lalani, A. S., & Tannock, I. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0676 · Cited by 65
“Hypoxia in tumors may select for a more malignant phenotype (1) and has been shown to be an independent predictor of poor clinical outcome, most likely due to both drug and radiation resistance, and also to an increased risk of metastasis (2).”
BackgroundA Novel Design Strategy for Stable Metal Complexes of Nitrogen Mustards as Bioreductive Prodrugs
Parker, L. L., Lacy, S. M., Farrugia, L. J., Evans, C., Robins, D. J., O’Hare, C. C., Hartley, J. A., Jaffar, M., & Stratford, I. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049866w · Cited by 60
Hypoxia-Dependent Retinal Toxicity of Bioreductive Anticancer Prodrugs in Mice
Lee, A. E., & Wilson, W. R. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8834 · Cited by 60
Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways
Blaydes, J. P., Craig, A. L., Wallace, M., Ball, H. M.-L., Traynor, N. J., Gibbs, N. K., & Hupp, T. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203773 · Cited by 66
“Cellular damaging agents as diverse as heat shock (Nitta et al., 1997), hypoxia (Graeber et al., 1996), perturbation of nucleotide metabolism (Linke et al., 1996), low extracellular pH (Williams et al., 1999), and TGF-b (Bellamy et al., 1997a) can also activate p53 function, thus suggesting either…”
BackgroundHypoxia-reoxygenation induces premature senescence in FA bone marrow hematopoietic cells
Zhang, X., Li, J., Sejas, D. P., & Pang, Q. (2005) · Blood · doi:10.1182/blood-2004-08-3033 · Cited by 59
“There were 3 sets of cells incubated in parallel: (1) the control cultures were incubated at 37°C in hyperoxia (humidified air with 21% O2, 5% CO2); (2) the reoxygenated cultures were subjected to 2 cycles of hypoxia (within a modular incubator chamber [BioSpherix, Redfield, NY] filled with 1% O2, 5% CO2, and balance…”
MethodGutierrez, L. (2003) · Carcinogenesis · doi:10.1093/carcin/24.2.199 · Cited by 60
Gene Therapy for Head and Neck Cancer
Gleich, L. L. (2000) · The Laryngoscope · doi:10.1097/00005537-200005000-00002 · Cited by 60
“Experiment 6 Purpose: Is the induction of apoptosis related to p53-mediated pathways? Cell stress can lead to apoptosis through tumor suppressor genes such as p53.(169) While one would not suppose p53 status to be significant to the outcome from an immunologically based gene therapy, p53 status was evaluated because n…”
BackgroundHighly Conserved RNA Sequences That Are Sensors of Environmental Stress
Spicher, A., Guicherit, O. M., Duret, L., Aslanian, A., Sanjines, E. M., Denko, N. C., Giaccia, A. J., & Blau, H. M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7371 · Cited by 60
“In addition, evidence is also accumulating that tumor hypoxia plays an integral role in the malignant progression of cancers (29).”
BackgroundSelf-citationImplications of intratumour heterogeneity for treatment stratification
Crockford, A., Jamal‐Hanjani, M., Hicks, J. B., & Swanton, C. (2013) · The Journal of Pathology · doi:10.1002/path.4270 · Cited by 66
“As well as limiting drug delivery, poor blood perfusion results in low oxygen concentrations (hypoxia) that may result in the selection for p53 –/– clones [59], up-regulation of the drug efflux pump MDR1 and altered pH [60,61].”
BackgroundHayano, K., Shuto, K., Koda, K., Yanagawa, N., Okazumi, S., & Matsubara, H. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181afbd79 · Cited by 59
“It was suggested that hypoxia is an important selective variable in the clonal evolution of tumors, promoting oncogenic mutations, cell survival, and more aggressive behavior in tumors, including cervical cancer and soft tissue sarcoma.(34) –37 We assume that these studies support our present observations that blood f…”
BackgroundResultPathophysiology of Solid Tumors
Vaupel, P. W. (2009) · Medical radiology · doi:10.1007/978-3-540-74386-6_4 · Cited by 59
Hypoxic Tumors and Their Effect on Immune Cells and Cancer Therapy
Yotnda, P., Wu, D., & Swanson, A. M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-786-0_1 · Cited by 70
“These residual surviving hypoxic cells often evolve into a more aggressive phenotype (36).”
BackgroundExtracellular Vesicles as Transmitters of Hypoxia Tolerance in Solid Cancers
Zonneveld, M. I., Keulers, T. G., & Rouschop, K. M. A. (2019) · Cancers · doi:10.3390/cancers11020154 · Cited by 61
“The pre-conditioning of cells with limited proliferative capacity indicates that cells have the capacity of reprogramming into a more hypoxia-resistant phenotype, rather than selection of cells with an intrinsic larger capacity to withstand hypoxic exposure, as often observed in cancer [26].”
BackgroundNew non-angiogenesis dependent pathways for tumour growth
Ribatti, D., Vacca, A., & Dammacco, F. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00267-3 · Cited by 59
“This apparent paradox is partially explained by the lower oxygen consumption rate of tumour cells [12], which are also known to tolerate oxygen deprivation [13].”
BackgroundLutterbach, J., & Guttenberger, R. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01382-1 · Cited by 59
Gilead, A., & Neeman, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900032 · Cited by 59
Tumour hypoxia in driving genomic instability and tumour evolution
Suvac, A., Ashton, J., & Bristow, R. G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00781-9 · Cited by 139
“Selection was attributed to decreased apoptosis under hypoxia 138,139 .”
Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia
Ramachandran, S., Ient, J., Göttgens, E., Krieg, A. J., & Hammond, E. M. (2015) · Genes · doi:10.3390/genes6040935 · Cited by 67
“tumor cells [105,106].”
Selvakumaran, M., Yao, K. S., Feldman, M. D., & O'Dwyer, P. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.029 · Cited by 60
“Apoptosis has long been known to be a consequence of hypoxia (17–19), and the response is in part p53dependent (35,36), especially in vivo, when overgrowth of p53- cells is favored by hypoxia (35,37), leading to the observation that hypoxia favors the evolution of a more aggressive cancer phenotype as a consequence of…”
BackgroundER proteostasis addiction in cancer biology: Novel concepts
Dufey, E., Urra, H., & Hetz, C. A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.04.003 · Cited by 61
Epel, B., Sundramoorthy, S. V., Barth, E. D., Mailer, C., & Halpern, H. J. (2011) · Medical Physics · doi:10.1118/1.3555297 · Cited by 60
Ménendez, S., Camus, S., Herreria, A., Paramonov, I., Batlle‐Morera, L., Collado, M., Pekařík, V., Maceda, I., Edel, M. J., Consiglio, A., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00754.x · Cited by 58
“In agreement, hypoxia directly activates the p53 pathway (Graeber et al., 1996), and a clear link between p53 and metabolism in cancer cells has recently emerged (Maddocks & Vousden, 2011).”
Background2017–2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
Zimmerman, S., Das, A., Wang, S., Julian, R. A., Gandhi, L., & Wolf, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.022 · Cited by 62
Detection of survivin and p53 in human oral cancer: Correlation with clinicopathologic findings
Khan, Z., Tiwari, R. P., Mulherkar, R., Sah, N. K., Prasad, G. B. K. S., Shrivastava, B. R., & Bisen, P. S. (2009) · Head & Neck · doi:10.1002/hed.21071 · Cited by 58
“Apoptotic cell death in cancer is always lower than that potentially predicted from the growth rate of the tumor, implying a general mechanism of apoptosis inhibition in malignancies.(7,12,32) In this context, and consistent with the paradigm of oral cancer described here, the broad distribution of survivin in neoplas…”
ResultMolecular Pathology of Non-Small-Cell Lung Cancer
Breuer, R. H. J., Postmus, P. E., & Smit, E. F. (2005) · Respiration · doi:10.1159/000085376 · Cited by 67
Newly discovered anti-inflammatory properties of the benzamides and nicotinamides
Pero, R. W., Axelsson, B., Siemann, D. W., Chaplin, D. J., & Dougherty, G. J. (1999) · Springer eBooks · doi:10.1007/978-1-4419-8740-2_18 · Cited by 58
Patterson, A. V., Williams, K. J., Cowen, R. L., Jaffar, M., Telfer, B. A., Saunders, M. P., Airley, R. E., Honess, D. J., van der Kogel, A. J., Wolf, C. R., et al. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301702 · Cited by 63
Inflammatory mediators are perpetuated in macrophages resistant to apoptosis induced by hypoxia
Yun, J. K., McCormick, T. S., Villabona, C., Judware, R., Espinosa, M. B., & Lapetina, E. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13903 · Cited by 58
Transcription Abnormalities Potentiate Apoptosis of Normal Human Fibroblasts
Anděra, L., & Wasylyk, B. (1997) · Molecular Medicine · doi:10.1007/bf03401721 · Cited by 62
p53-dependent induction of WAF1 by a low-pH culture condition in human glioblastoma cells.
Ohtsubo, T., Wang, X., Takahashi, A., Ohnishi, K., Saito, H., Song, C. W., & Ohnishi, T. (1997) · PubMed · Cited by 58
Induction of p21WAF/CIP1 during Hyperoxia
McGrath, S. A. (1998) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.18.2.2964m · Cited by 58
Zhang, C., Liu, Q., Li, M., Lin, S., Peng, Y., Wu, D., Li, T. Y., Fu, Q., Jia, W., Wang, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.90 · Cited by 60
Targeting Tumor Hypoxia With Hypoxia-Activated Prodrugs
Yeh, J. J., & Kim, W. Y. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0759 · Cited by 61
Tanaka, T. Q., Furukawa, T., Fujieda, S., Kasamatsu, S., Yonekura, Y., & Fujibayashi, Y. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.05.005 · Cited by 57
Cho, W.-K., Seong, Y. R., Lee, Y. H., Kim, M. J., Hwang, K., Yoo, J., Choi, S., Jung, C., & Im, D. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.023 · Cited by 66
“Most malignant tumor cells, which have survived under hypoxia, are likely susceptible to genetic alterations, such as active HIF-1a under normoxia and mutated p53 [5].”
BackgroundInfluentialGansauge, S., Gansauge, F., Gause, H., Poch, B., Schoenberg, M. H., & Beger, H. G. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00059-8 · Cited by 55
Tenjo, T., Toyoda, M., Okuda, J., Watanabe, I., Yamamoto, T., Tanaka, K., Ohtani, M., Nohara, T., Kawasaki, H., & Tanigawa, N. (2000) · Oncology · doi:10.1159/000012078 · Cited by 60
The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer
Metin, C. U., & Özcan, G. (2022) · Cancers · doi:10.3390/cancers14112711 · Cited by 58
“One important caveat for the inhibition or down-regulation of HIF-1α is the observation that cancer cells selected under hypoxia and expressing high levels of HIF-1α may mostly have loss-of-function mutations in p53, which will render them resistant to the apoptotic effect of any intervention [78].”
BackgroundMultimodality imaging of hypoxia in preclinical settings.
Mason, R. P., Zhao, D., Pacheco‐Torres, J., Cui, W., Kodibagkar, V. D., Gulaka, P., Hao, G., Thorpe, P. E., Hahn, E. W., & Peschke, P. (2010) · PubMed · Cited by 70
Cancer Stem Cells Under Hypoxia as a Chemoresistance Factor in the Breast and Brain
Crowder, S. W., Balikov, D. A., Hwang, Y., & Sung, H. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-013-0035-6 · Cited by 59
“recognized to include: – increased genomic instability and aberrant cell cycling [8, 11–16]; – dysregulated reactive oxygen species and redox mechanisms [17–22]; – a metabolic shift toward aerobic glycolysis [23–27]; and – mitigated expression of pro-apoptotic factors [28–32].”
Marotta, D., Karar, J., Jenkins, W. T., Kumanova, M., Jenkins, K. W., Tobias, J. W., Baldwin, D., Hatzigeorgiou, A., Alexiou, P., Evans, S. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3061 · Cited by 55
Self-citationUpregulation of Wnt signaling under hypoxia promotes lung cancer progression
Hong, C.-F., Chen, W.-Y., & Wu, C. (2017) · Oncology Reports · doi:10.3892/or.2017.5807 · Cited by 58
Next-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”
Menon, V., & Brash, D. E. (2023) · Mutation Research - Reviews in Mutation Research · doi:10.1016/j.mrrev.2023.108471 · Cited by 48
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.